CDRH dispute resolution guidance
This article was originally published in The Gray Sheet
Executive Summary
Publication is anticipated in the next couple of weeks, Center for Devices and Radiological Health Director Bruce Burlington reports at the FDLI annual meeting Dec. 16. The document is expected to state that members of FDA's Medical Device Advisory Committee will be called upon when necessary to address device-related scientific controversies ("The Gray Sheet" July 6, p. 17). A plan to name a CDRH ombudsman to assist in the review of such matters has been put on hold because of budget constraints, staffers say
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.